As of 2025-09-18, the Intrinsic Value of Terns Pharmaceuticals Inc (TERN) is -5.25 USD. This TERN valuation is based on the model Peter Lynch Fair Value. With the current market price of 7.40 USD, the upside of Terns Pharmaceuticals Inc is -170.88%.
Based on its market price of 7.40 USD and our intrinsic valuation, Terns Pharmaceuticals Inc (TERN) is overvalued by 170.88%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.25 - -5.25 | -5.25 | -170.88% |
| P/E | (19.93) - (21.06) | (20.67) | -379.3% |
| DDM - Stable | (11.63) - (45.07) | (28.35) | -483.1% |
| DDM - Multi | (10.67) - (32.21) | (16.04) | -316.7% |
| Market Cap (mil) | 647.57 |
| Beta | 2.21 |
| Outstanding shares (mil) | 87.51 |
| Enterprise Value (mil) | 523.57 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.20% |
| Cost of Debt | 5.00% |
| WACC | 6.59% |